Proven COVID‐19—associated pulmonary aspergillosis in patients with severe respiratory failure

• DOI: 10.1111/myc.13342
• Publication Date: 2021-06-22T19:20:29Z
• Authors: Francesco Fortarezza; Annalisa Boscolo; Federica Pezzuto; Francesca Lunardi; Manuel Jesús Acosta; Chiara Giraudo; Claudia Del Vecchio; Nicolò Sella; Ivo Tiberio; Ilaria Godi; Annamaria Cattelan; Luca Vedovelli; Dario Gregori; Roberto Vettor; Pierluigi Viale; Paolo Navalesi; Fiorella Calabrese
• Keywords: Pandemic; Concomitant

An increasing number of reports have described the COVID-19-associated pulmonary aspergillosis (CAPA) as being a further contributing factor to mortality. Based on recent consensus statement supported by international medical mycology societies, it has been proposed define CAPA possible, probable, or proven basis sample validity and thus diagnostic certainty. Considering current challenges associated with diagnoses, there is pressing need study epidemiology CAPA.We report incidence histologically diagnosed in series 45 consecutive COVID-19 laboratory-confirmed autopsies, performed at Padova University Hospital during first second wave pandemic. Clinical data, laboratory data radiological features were also collected for each case.Proven was detected 9 (20%) cases, mainly pandemic (7/17 vs. 2/28 wave). The population patients consisted seven males two females, median age 74 years. Seven admitted intensive care unit. All had least comorbidities, concomitant lung diseases three cases.We found high frequency among severe confirming part alarming epidemiological this important complication recently reported probable CAPA.